Pictet Asset Management Holding SA Has $17.46 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Pictet Asset Management Holding SA grew its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 4.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 580,428 shares of the company’s stock after buying an additional 23,156 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.05% of Teva Pharmaceutical Industries worth $17,461,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. AQR Capital Management LLC grew its position in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after acquiring an additional 4,732 shares during the last quarter. Focus Partners Wealth raised its position in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the last quarter. Franklin Resources Inc. acquired a new position in Teva Pharmaceutical Industries in the second quarter worth $255,000. Flow Traders U.S. LLC bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $238,000. Finally, Cerity Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock worth $768,000 after purchasing an additional 1,291 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on TEVA shares. Bank of America lifted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Buying and Selling

In other news, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the sale, the insider owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 465,931 shares of company stock worth $16,332,989. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Trading Up 3.3%

Shares of TEVA opened at $34.55 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The firm has a market capitalization of $39.73 billion, a PE ratio of 25.98, a price-to-earnings-growth ratio of 4.08 and a beta of 0.86. The stock’s fifty day simple moving average is $33.89 and its 200-day simple moving average is $32.54.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.